Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.67 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE6A | P16499 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327066 | 0.80 | MTOR (1.00) | MTORERN1PIK3CASUV39H2JAK2 | |
| SCHEMBL3326770 | 0.76 | MTOR (1.00) | MTORERN1PIK3CASUV39H2JAK2 | |
| SCHEMBL3326778 | 0.75 | MTOR (0.68) | MTORERN1PIK3CASUV39H2JAK2 | |
| SCHEMBL3327820 | 0.73 | PIK3CA (0.46) | MTORPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL3327637 | 0.71 | MTOR (1.00) | MTORERN1PIK3CAJAK2JAK3 | |
| SCHEMBL1310166 | 0.68 | MTOR (1.00) | MTORERN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL5457199 | 0.67 | PIK3CA (0.55) | MTORPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL1309671 | 0.66 | MTOR (0.73) | MTORERN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3327130 | 0.66 | MTOR (0.62) | MTORERN1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL24140809 | 0.66 | MTOR (0.51) | MTORERN1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | MTOR 3648/4885ERN1 3579/4885PIK3CA 2265/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | MTOR 3596/4885ERN1 3561/4885PIK3CA 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.